ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

CM551

A development code.

Its studies are mostly in Inflammatory Bowel Diseases, led by Keymed Biosciences.

Furthest: phase 1, since Oct 22, 20261 company-led study, 1 open or runningNext primary completion: Sep 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Keymed Biosciences11 open or runningphase 1since Oct 22, 2026Oct 22, 2026Sep 2027phase 1 · NCT07900945

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 22, 2026First study: phase 1 study in Inflammatory Bowel DiseasesFirst studyNCT07900945 · 48 planned · China

Ahead

  1. Sep 2027Primary completion: phase 1 study in Inflammatory Bowel DiseasesNCT07900945

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07900945Inflammatory Bowel Diseases · China1Not yet recruitingSep 202748

How it is read

Names in the registry

  • “CM551”, 2 entries

Codes read as this program: CM551.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.